Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Ibudilast, a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE)-3, -4, -10, and -11, and macrophage migration inhibitory factor (MIF), shows promise as a novel pharmacotherapy for alcohol use disorder (AUD). However, the mechanisms of action underlying ibudilast’s effects on the human brain remain largely unknown. Thus, the current study examined the efficacy of ibudilast to improve negative mood, reduce heavy drinking, and attenuate neural reward signals in individuals with AUD. Fifty-two nontreatment-seeking individuals with AUD were randomized to receive ibudilast (n = 24) or placebo (n = 28). Participants completed a 2-week daily diary study during which they filled out daily reports of their past day drinking, mood, and craving. Participants completed an functional magnetic resonance imaging (fMRI) alcohol cue-reactivity paradigm half-way through the study. Ibudilast did not have a significant effect on negative mood (β = −0.34, p = 0.62). However, ibudilast, relative to placebo, reduced the odds of heavy drinking across time by 45% (OR = 0.55, (95% CI: 0.30, 0.98)). Ibudilast also attenuated alcohol cue-elicited activation in the ventral striatum (VS) compared to placebo (F(1,44) = 7.36, p = 0.01). Alcohol cue-elicited activation in the VS predicted subsequent drinking in the ibudilast group (F(1,44) = 6.39, p = 0.02), such that individuals who had attenuated ventral striatal activation and took ibudilast had the fewest number of drinks per drinking day in the week following the scan. These findings extend preclinical and human laboratory studies of the utility of ibudilast to treat AUD and suggest a biobehavioral mechanism through which ibudilast acts, namely, by reducing the rewarding response to alcohol cues in the brain leading to a reduction in heavy drinking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Beck, A. T., Steer, R. A., & Brown, G. (2011) · PsycTESTS Dataset · doi:10.1037/t00742-000 · Cited by 7,535
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
SULLIVAN, J. T., SYKORA, K., SCHNEIDERMAN, J., NARANJO, C. A., & SELLERS, E. M. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00737.x · Cited by 1,988
Psychometric properties of the Penn Alcohol Craving Scale
Flannery, B. A., Volpicelli, J. R., & Pettinati, H. M. (1999) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.1999.tb04349.x · Cited by 852 · cited 1×
“Participants also completed assessments regarding their alcohol use, including: Alcohol Use Disorder Identification Test (AUDIT) [31] and Alcohol Dependence Scale (ADS) [32], which measure severity of alcohol use problems, Penn Alcohol Craving Scale (PACS) [33] and Obsessive Compulsive Drinking Scale (OCDS) [34], whic…”
MethodShort Form of the Profile of Mood States (POMS-SF): Psychometric information.
Curran, S. L., Andrykowski, M. A., & Studts, J. L. (1995) · Psychological Assessment · doi:10.1037//1040-3590.7.1.80 · Cited by 808
Mitchell, R. A., Liao, H., Chesney, J., Fingerle-Rowson, G., Baugh, J., David, J., & Bucala, R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012511599 · Cited by 622
Inflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609
Schacht, J. P., Anton, R. F., & Myrick, H. (2013) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00464.x · Cited by 583
Leclercq, S., Cani, P. D., Neyrinck, A. M., Stärkel, P., Jamar, F., Mikolajczak, M., Delzenne, N. M., & de Timary, P. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.04.001 · Cited by 310
Research works printed but not linked: 37
- Ray, LA. et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abus. 45, 124–40 (2019). · DOI · Paper page
- Litten, RZ. et al. Medications development to treat alcohol dependence: a vision for the next decade. Addiction Biol. 17, 513–27 (2012). · DOI · Paper page
- Litten, RZ., Falk, DE., Ryan, ML. & Fertig, JB. Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development. Alcohol Clin Exp Res. 40, 1368–79 (2016). · DOI · Paper page
- Mayfield, J. & Harris, RA. The neuroimmune basis of excessive alcohol consumption. Neuropsychopharmacology. 42, 376 (2017). · DOI · Paper page
- Crews, FT. et al. Neuroimmune function and the consequences of alcohol exposure. Alcohol Res. 37, 331–51 (2015).
- He, J. & Crews, FT. Increased MCP-1 and microglia in various regions of the human alcoholic brain. Exp Neurol. 210, 349–58 (2008). · DOI · Paper page
- Koob, GF. & Volkow, ND. Neurocircuitry of addiction. Neuropsychopharmacology. 35, 217–38 (2010). · DOI · Paper page
- Coleman LG, Crews FT. Innate immune signaling and alcohol use disorders. In: Grant KA, Lovinger DM, editors. The neuropharmacology of alcohol. Cham: Springer International Publishing; 2018. p. 369–96. · DOI
- Gibson, LC. et al. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol 538, 39–42 (2006). · DOI
- Cho, Y. et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA. 107, 11313–18 (2010). · DOI · Paper page
- Hertz, AL. et al. Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages. Proc Natl Acad Sci USA. 106, 21978–83 (2009). · DOI · Paper page
- Gobejishvili, L., Barve, S., Joshi-Barve, S. & McClain, C. Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 295, G718–G24 (2008). · DOI · Paper page
- Mizuno, T. et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 46, 404–11 (2004). · DOI · Paper page
- Fox, RJ. et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 379, 846–55 (2018). · DOI · Paper page
- Pérez-Torres, S. et al. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H] rolipram binding autoradiography: comparison with monkey and rat brain. J Chem Neuroanat. 20, 349–74 (2000). · DOI · Paper page
- Liu, X., Zhong, P., Vickstrom, C., Li, Y. & Liu, QS. PDE4 inhibition restores the balance between excitation and inhibition in VTA dopamine neurons disrupted by repeated in vivo cocaine exposure. Neuropsychopharmacology. 42, 1991–99 (2017). · DOI
- Grodin, EN. & Ray, LA. The use of functional magnetic resonance imaging to test pharmacotherapies for alcohol use disorder: a systematic review. Alcohol Clin Exp Res. 43, 2038–56 (2019). · DOI
- Courtney, KE., Schacht, JP., Hutchison, K., Roche, DJ. & Ray, LA. Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addiction Biol. 21, 3–22 (2016). · DOI · Paper page
- Schacht, JP. et al. Predictors of naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status. Neuropsychopharmacology. 42, 2640–53 (2017). · DOI
- Anton, RF., Moak, DH. & Latham, P. The obsessive compulsive drinking scale: a self‐rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 19, 92–99 (1995). · DOI · Paper page
- Adams, ZW., Schacht, JP., Randall, P. & Anton, RF. The reasons for heavy drinking questionnaire: factor structure and validity in alcohol-dependent adults involved in clinical trials. J Stud Alcohol Drugs. 77, 354–61 (2016). · DOI
- Heatherton, TF., Kozlowski, LT., Frecker, RC. & Fagerstrom, KO. The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addiction 86, 1119–27 (1991). · DOI · Paper page
- Bohn, MJ., Krahn, DD. & Staehler, BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 19, 600–06 (1995). · DOI · Paper page
- Schacht, JP. et al. Stability of fMRI striatal response to alcohol cues: a hierarchical linear modeling approach. Neuroimage 56, 61–68 (2011). · DOI · Paper page
- Jenkinson, M., Bannister, P., Brady, M. & Smith, S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17, 825–41 (2002). · DOI · Paper page
- Andersson JL, Jenkinson M, Smith S. Non-linear registration aka spatial normalisation FMRIB Technial Report TR07JA2. FMRIB Analysis Group of the University of Oxford; 2007:1–22.
- Liang, K-Y. & Zeger, SL. Longitudinal data analysis using generalized linear models. Biometrika 73, 13–22 (1986). · DOI · Paper page
- Ziegler A. Generalized estimating equations. Springer Science & Business Media; 2011. · DOI
- Mann, K., Aubin, H-J., Charlet, K. & Witkiewitz, K. Can reduced drinking be a viable goal for alcohol dependent patients?. World Psychiatry 16, 325–26 (2017). · DOI
- Hasin, DS. et al. Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry 4, 469–76 (2017). · DOI · Paper page
- Ramirez, D., & Smith, SM. Regulation of dopamine signaling in the striatum by phosphodiesterase inhibitors: novel therapeutics to treat neurological and psychiatric disorders. Cent Nerv Syst Agents Med Chem. 14, 72–82 (2014). · DOI
- Bland, ST., Hutchinson, MR., Maier, SF., Watkins, LR. & Johnson, KW. The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain Behav Immun. 23, 492–97 (2009). · DOI · Paper page
- Airaksinen, MS. & Saarma, M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 3, 383–94 (2002). · DOI · Paper page
- Barak, S., Carnicella, S., Yowell, QV. & Ron, D. Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking. J Neurosci. 31, 9885–94 (2011). · DOI · Paper page
- Heberlein, A. et al. BDNF and GDNF serum levels in alcohol-dependent patients during withdrawal. Prog NeuroPsychopharmacol Biol Psychiatry 34, 1060–64 (2010). · DOI
- Fox, HC., Milivojevic, V., Angarita, GA., Stowe, R. & Sinha, R. Peripheral immune system suppression in early abstinent alcohol-dependent individuals: Links to stress and cue-related craving. J Psychopharmacol. 31, 883–92 (2017). · DOI
- Ray, LA., Bujarski, S., Yardley, MM., Roche, DJ. & Hartwell, EE. Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter?. Am J Drug Alcohol Abus. 43, 703–10 (2017). · DOI
Cited by
Hatoum, A. S., Colbert, S. M. C., Johnson, E. C., Huggett, S. B., Deak, J. D., Pathak, G. A., Jennings, M. V., Paul, S. E., Karcher, N. R., Hansen, I., et al. (2023) · Nature Mental Health · doi:10.1038/s44220-023-00034-y · Cited by 241
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Another recent 2-week RCT enrolling 52 participants found that ibudilast also significantly decreased the odds of heavy drinking during the trial by 45% compared to placebo and attenuated neural response to alcohol cues in the ventral striatum [193, 194].”
BackgroundSelf-citationPreclinical and clinical evidence for suppression of alcohol intake by apremilast
Grigsby, K. B., Mangieri, R. A., Roberts, A. J., Lopez, M. F., Firsick, E. J., Townsley, K. G., Beneze, A., Bess, J., Eisenstein, T. K., Meissler, J. J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci159103 · Cited by 64
“Ibudilast did not reduce the overall probability of drinking in a clinical POC study, but did reduce the number of heavy drinking days in individuals with AUD (57).”
Varodayan, F. P., Pahng, A. R., Davis, T. D., Gandhi, P., Bajo, M., Steinman, M. Q., Kiosses, W. B., Blednov, Y. A., Burkart, M. D., Edwards, S., et al. (2023) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2023.02.020 · Cited by 50
Grodin, E. N., Nieto, S. J., Meredith, L. R., Burnette, E., O'Neill, J., Alger, J., London, E. D., Miotto, K., Evans, C. J., Irwin, M. R., et al. (2022) · Addiction Biology · doi:10.1111/adb.13182 · Cited by 25
“Results from this preliminary study provide a potential proof of mechanism for ibudilast, such that it may work through a neuroprotective pathway to reduce alcohol use in individuals with AUD.”
BackgroundMethodSelf-citation
Metadata
- Authors
- Grodin, E. N., Bujarski, S., Towns, B., Burnette, E., Nieto, S., Lim, A., Lin, J., Miotto, K., Gillis, A., Irwin, M. R., Evans, C., & Ray, L. A.
- Venue
- Translational Psychiatry
- Published
- 2021-06-12
- Volume
- 11
- Issue
- 1
- Pages
- 355-355
- ISSN
- 2158-3188 (ISSN-L)
- OpenAlex
- W3170101799
- Cited by
- 78
- References
- 13
- FWCI
- 8.12
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (P50 DA005010-33)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial. https://app.cochat.ai/papers/10.1038/s41398-021-01478-5
- The paper
- Grodin, E. N., Bujarski, S., Towns, B., Burnette, E., Nieto, S., Lim, A., Lin, J., Miotto, K., Gillis, A., Irwin, M. R., Evans, C., & Ray, L. A. (2021). Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial. Translational Psychiatry. https://doi.org/10.1038/s41398-021-01478-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.